in mammals, SETD3 is the only enzyme that catalyses the His73 methylation of actin, and that actin is the only substrate of SETD3. They also show that SETD3 and His73 methylation of actin are present in a wide range of organ isms, including plants and animals, but that SETD3 is not present in budding yeast, which also lacks His73methylated actin.
Why does SETD3 methylate actin, but not other proteins? To answer this question, Wilkinson et al. determined the atomic struc ture of SETD3 in complex with a short chain of amino acids (a peptide) that has the same aminoacid sequence as the region of actin around His73. They found that this peptide occupies an extended groove in the domain of SETD3 that is responsible for the enzyme's methyltransferase activity. The interface between SETD3 and the actin peptide has many specific interactions, which explain why SETD3 binds to and methylates only actin.
To examine the biological functions of this posttranslational modification, Wilkinson et al. generated 'knockout' mice and cell lines in which the gene encoding SETD3 was in active. They observed that actin is no longer methyl ated in these models. Surprisingly, the mice lacking SETD3 seemed to be healthy, which demonstrates that methylation of actin at His73 is not essential in mammals. However, female mice lacking SETD3 took longer to give birth than did mice in which this protein was present. The delay resulted from defective contraction of certain muscles of the uterus during labour. Moreover, the migration of SETD3knockout cells in culture was slower than that of wildtype cells. Finally, nonmethylated actin purified from the SETD3knockout cells polymerized slightly more slowly than did methylated actin, and had a faster rate of exchange of nucleo tides on single actin molecules than did actin purified from wildtype cells.
These experiments provide evidence that, despite being evolutionarily conserved across a broad group of organisms, methylation at His73 is not essential for the normal functioning of actin. Instead, this modification seems to finetune the protein's biochemical properties and cellular roles.
Future studies should investigate the SETD3knockout mice in more detail for possible additional differences from wild type mice, and should examine the effects of SETD3 deletion in other model organisms. Also, the effects of His73 methylation on actin biochemistry should be studied more precisely. Previously, analysing these effects was possible only by mutating the His73 residue in actin or by producing human actin in yeast, in which this protein cannot be methylated 9, 10 . The new findings will enable careful sidebyside com parison of wildtype actin and actin that lacks methylation only at His73.
Because His73 is close to the nucleotide binding site of actin, it will be especially interesting to study how this modification affects the functions of proteins that catalyse nucleotide exchange on actin 11 and that rely on ATP hydrolysis and subsequent release of free phosphate for their interactions with actin filaments 12 . ■ 4 describe on page 361 a potential way of tackling this problem -a miniature implanted device that can sense and control bladder function in rats.
Pekka Lappalainen is in the HiLIFE
Rather than modulating nerve activity through the direct use of electrical stimuli, the authors harnessed an established technique called optogenetics, in which nerve cells in the bladder were genetically modified to express a lightsensitive receptor protein that can inhibit nervecell activation. Mickle and col leagues implanted a stretchable, highprecision strain sensor around each animal's bladder that measured changes in bladder circumference over time. The bladder sensor was connected
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Implant aids responsive bladder control
Implants that electrically stimulate nerves continuously to treat disease can cause off-target effects and pain. An implant that uses light to modulate the activity of genetically modified nerve cells might offer a solution. See Letter p.361 to lightemitting diodes (LEDs). These components were connected by wires to a flexible basestation device implanted in the abdomen. The base station was powered wirelessly by interactions with an element incorporated below the housing cage (Fig. 1) .
The bladderstretch sensor communicated data to the base station, which then wirelessly transmitted this information to an external device that recorded and monitored bladder function. If the external device detected signs of abnormal bladder function -for example, unnecessarily frequent bladder emptying -it transmitted a signal wirelessly to the base sta tion. This made the LEDs turn on, causing lightmediated inhibition of sensory neu rons in the bladder that thereby affected the frequency of bladder emptying. This type of arrangement is called a closedloop system, in which the output of the system -in this case, bladder size changes -is monitored and feeds back into the system as an input signal. This is advantageous in this context because it triggers the modulation of nervecell activity only when needed, providing a targeted, realtime control system.
The authors tested how effective their system was for managing the bladder dys function that arises when rats are injected with the drug cyclophosphamide. This causes an inflammatory response and an increase in the number of episodes of bladder emptying compared with that in animals that do not receive cyclophosphamide. The authors' sys tem detected dysfunctional patterns of blad der emptying and consequently inhibited the organ's sensory nerves and restored a normal pattern of urination frequency.
Mickle and colleagues' device is possible only because of many recently developed rel evant tools. The authors needed implantable flexible sensors and stretchable electronics that can detect organdimension changes in a way that does not affect organ function [5] [6] [7] [8] . Developments in the field of optogenetics, wireless data and energy transfer also provided crucial technologies needed for the system to function.
The animal model of overactive bladder function that the authors chose for their sys tem reveals the sophisticated capabilities of this technology. Whether this versatile plat form could be adapted to treat other diseases should be explored. Mickle and colleagues' work might have major implications for efforts to alleviate organ dysfunction and to modulate pain. However, it was not possible to determine whether the pain caused by bladder infection and the inflammation that can be associated with bladder dysfunction can be lessened by using the authors' approach, and the effects of inhibition of sensory nerves using this method should be a topic for further investigation.
It was previously shown 9 that, for a surgically removed rabbit heart being kept functional in the laboratory, a stretchable, sleevelike electronic device surrounding the heart can detect data such as tempera ture, pH and mechanical strain. If such a heartmonitoring device could be modified to incorporate the closedloop control system developed by Mickle and colleagues, it might provide realtime feedback that could be used to modulate the activity of the implanted pumps or sleeves (called ventricular assist devices) that aid people who have a weakened heart 10, 11 . Or, one day, a closedloop system might be used to detect stretching of the stom ach and relay this information to drive a feeling of fullness, as a way of managing obesity. Could this closedloop system have the potential to be adapted into a medical device that enables normal bowel emptying for people with faecal incontinence caused by nerve damage?
The approach developed by Mickle and colleagues has several key features. Using an optical system to modulate nervecell function provides greater stability and temporal preci sion than does electrical stimulation. Flexible electronics that conform to an organ surface offer a stable interface in which the electronic device matches the mechanical properties of the associated tissue. If it were possible to use input from physical cues such as changes in organ geometry, bloodflow dynamics or tem perature in a closedloop therapeutic device, this would open up a new way of thinking about how to harness biological sensing for clinical purposes. In contrast to current sensor techniques, which use cues such as chemical signals in bloodglucose monitors or elec trical signals in heart pacemakers, focusing instead on easily measured physical cues might substantially increase the number of ways of assessing the function of an organ.
This study provides a groundbreaking dem onstration of how a fully closedloop system can sense and control organ function, but there are some drawbacks. The wirelesspowering mechanism requires a device that is placed underneath the animal's cage, so alternative strategies would be needed to provide a wire less energy source for clinical use. Another disadvantage is that the optogenetics approach relies on the genetic modification of cells. In this case, a virus was used to introduce the engineered gene into bladder cells by injection into the bladder wall after a surgical incision through skin and muscle to expose the bladder. Moreover, this step was carried out some time before device implantation, and a requirement for repeated bouts of surgery could generate a barrier to the clinical implementation of this approach. Furthermore, if part of the system failed and needed to be replaced, additional invasive surgical procedures would be needed to remedy the problem.
The body's longterm response to the presence of a stretchable sensor around the bladder is unknown. It is also of concern that associated tissue damage might occur, such as the formation of excess fibrous connective tissue (fibrosis), or whether adhesions to sur rounding tissue might arise that could limit implant function and have adverse effects on organ function.
Mickle and colleagues have taken a major step forward for this field by developing a thera peutic system that enables specific and stable stimulation of the nervous system. If 4 have developed an approach that uses genetic engineering and an implanted device to generate a selfadjusting system (called a closedloop system) that regulates nervecell activity to treat organ dysfunction in rats. The authors used animals that had been genetically engineered to express a lightsensitive protein in sensory nerve cells in their bladder. A stretchable sensor implanted in the bladder monitored the organ's circumference, and it was attached to lightemitting diodes (LEDs). These bladder components were connected by wires to an implanted basestation electronic device in the abdomen that was powered wirelessly by a transmitter in the animal's cage. The base station received information from the bladder's stretch sensor and transmitted this wirelessly to an external userinterface device that tracked the bladder data. If the data indicated abnormally frequent bladder emptying, which happened when animals received the molecule cyclophosphamide (not shown), the external device transmitted a wireless signal back to the base station that caused the LEDs to turn on. Their illumination inhibited the genetically engineered nerve cells and consequently prevented an abnormally high frequency of urination. When the star has consumed all of its nuclear fuel, its core collapses. This leads to a strong blast wave that ejects the stellar envelope at a velocity of about 1-3% of the speed of light, producing a supernova explosion 1 . In rare cases, the collapsing core also launches an energetic beam of matter and radiation, known as a jet, through the stellar envelope at almost the speed of light 2 . The jet emerges from the stellar surface and generates a bright burst of γrays, which can be seen only when the jet points directly towards Earth. On page 324, Izzo et al. 3 report spectroscopic observations of a supernova associated with a γray burst, improving our understanding of the interplay between the jet and the exploding stellar envelope. Theory predicts that, as a jet pushes its way through a stellar envelope, it heats the gas that surrounds its path, producing a highly pres surized, hot bubble known as a cocoon [4] [5] [6] ( Fig. 1a) . As the jet breaks out of the star, so does the cocoon 7 ( Fig. 1b ; see also the movies at go.nature.com/2sdoeao). The cocoon carries information about the interaction between the jet and the envelope and opens a window on the inner workings of the explosion.
The predicted signature of the cocoon initially includes a relatively faint flare of γrays that is emitted when the cocoon breaks out of the stellar envelope [8] [9] [10] . This is followed by a fading signal that is seen first in Xrays and later in ultraviolet and optical light 11 . In addi tion, the cocoon spreads sideways, engulfing the expanding envelope so that the supernova light must pass through the cocoon material on its way to Earth. During the first few days after the explosion, this passage leaves an imprint of broad absorption features on the spectrum of light from the supernova 12 . Later, as the cocoon expands, it becomes fully transparent, and the absorption features disappear.
For decades, astronomers have been observing the emissions from ejected enve lopes and from jets -the supernovae and the γray bursts, respectively. However, although cocoons are predicted to transport as much energy as the other two components 11 , iden tifying their observational signatures turned out to be extremely difficult. When a jet is pointing towards Earth, the γray burst and the afterglow of the burst outshine the cocoon emission, as well as the supernova light, for several days. And when a jet is pointing away from Earth, the supernova is usually detected too late, after the absorption signal has disap peared. Izzo and colleagues present observa tions of an event in which a γray burst is seen, but the afterglow of the burst is faint enough to opto genetics approaches are approved for specific clinical applications, this type of closedloop system might be poised to have a key role in driving a transformative shift towards the use of such strategies to treat human disease. ■ Ellen T. Roche Figure 1 | Jets and cocoons in supernova explosions. a, During the death of a massive star, the stellar envelope is ejected to produce a supernova. In rare cases, the core of the star launches (blue arrow) a narrow beam of matter and radiation called a jet through the envelope, generating a hot bubble known as a cocoon. Izzo et al. 3 report observations of such a cocoon in a particular supernova. b, If the jet successfully breaks out of the stellar envelope, it produces a bright burst of γrays. The cocoon also breaks out, and spreads sideways (red arrows) to engulf the star. Supernova light from the envelope is partially absorbed as it passes through the cocoon on its way to Earth. c, In other supernovae, jets can be 'choked' -they lose all of their energy while still inside the envelope. However, the cocoon can still break out and form an outflow similar to that of the cocoon of a successful jet. 
ASTROPHYSICS
Heart of a stellar explosion revealed
During the deaths of some massive stars, a narrow beam called a jet is launched through the stellar envelope, leaving an imprint that is difficult to detect. Such an imprint has now been seen in unprecedented detail. See Letter p.324
